Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 6/2018

Open Access 01-06-2018 | Review

Immunoglobulin A and liver diseases

Authors: Tatsuo Inamine, Bernd Schnabl

Published in: Journal of Gastroenterology | Issue 6/2018

Login to get access

Abstract

Immunoglobulin A (IgA) is a major immunoglobulin isotype in the gut and plays a role in maintenance of gut homeostasis. Secretory IgA (SIgA) has multiple functions in the gut, such as to regulate microbiota composition, to protect intestinal epithelium from pathogenic microorganisms, and to help for immune-system development. The liver is the front-line organ that receives gut-derived products through the portal vein, implying that the liver could be severely affected by a disrupted intestinal homeostasis. Indeed, some liver diseases like alcoholic liver disease are associated with an altered composition of gut microbiota and increased blood endotoxin levels. Therefore, deficiency of SIgA function appears as a significant factor for the pathogenesis of liver diseases associated with altered gut microbiome. In this review, we describe SIgA functions on the gut microbiome and discuss the role of IgA for liver diseases, especially alcoholic liver disease and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Literature
1.
Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780–5.PubMedPubMedCentralCrossRef
2.
Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139(1844–1854):e1.
3.
Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4.PubMedCrossRef
4.
Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–6.PubMedCrossRef
5.
Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.PubMedCrossRef
6.
Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103.PubMedCrossRef
7.
Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451–63.PubMedPubMedCentralCrossRef
8.
Kang D-W, Park JG, Ilhan ZE, et al. Reduced incidence of prevotella and other fermenters in intestinal microflora of autistic children. PLoS One. 2013;8:e68322.PubMedPubMedCentralCrossRef
9.
Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562–72.PubMedCrossRef
10.
Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601–9.PubMedCrossRef
11.
Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302:G168–75.PubMedCrossRef
12.
Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. 2010;10:159–69.PubMedCrossRef
13.
Conley ME, Delacroix DL. Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense? Ann Intern Med. 1987;106:892–9.PubMedCrossRef
14.
Strugnell RA, Wijburg OLC. The role of secretory antibodies in infection immunity. Nat Rev Microbiol. 2010;8:656–67.PubMedCrossRef
15.
16.
17.
Mirpuri J, Raetz M, Sturge CR, et al. Proteobacteria-specific IgA regulates maturation of the intestinal microbiota. Gut Microbes. 2014;5:28–39.PubMedCrossRef
18.
19.
Wei M, Shinkura R, Doi Y, et al. Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol. 2011;12:264–70.PubMedCrossRef
20.
21.
Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513–24.PubMedCrossRef
22.
Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65:2035–44.PubMed
23.
Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535:75–84.PubMedCrossRef
24.
Fagarasan S, Kawamoto S, Kanagawa O, et al. Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. Annu Rev Immunol. 2010;28:243–73.PubMedCrossRef
25.
26.
Rogier EW, Frantz AL, Bruno MEC, et al. Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. Proc Natl Acad Sci USA. 2014;111:3074–9.PubMedPubMedCentralCrossRef
27.
Pabst O, Cerovic V, Hornef M. Secretory IgA in the coordination of establishment and maintenance of the microbiota. Trends Immunol. 2016;37:287–96.PubMedCrossRef
28.
Weemaes C, Klasen I, Goertz J, et al. Development of immunoglobulin A in infancy and childhood. Scand J Immunol. 2003;58:642–8.PubMedCrossRef
29.
Brown WR, Kloppel TM. The liver and IgA: immunological, cell biological and clinical implications. Hepatology. 1989;9:763–84.PubMedCrossRef
30.
Moro-Sibilot L, Blanc P, Taillardet M, et al. Mouse and human liver contain immunoglobulin A—secreting cells originating from Peyer’s patches and directed against intestinal antigens. Gastroenterology. 2016;151:311–23.PubMedCrossRef
31.
Peterson DA, McNulty NP, Guruge JL, et al. IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe. 2007;2:328–39.PubMedCrossRef
32.
Cullender TC, Chassaing B, Janzon A, et al. Innate and adaptive immunity interact to quench microbiome flagellar motility in the gut. Cell Host Microbe. 2013;14:571–81.PubMedPubMedCentralCrossRef
33.
Fransen F, Zagato E, Mazzini E, et al. BALB/c and C57BL/6 mice differ in polyreactive IgA abundance, which impacts the generation of antigen-specific IgA and microbiota diversity. Immunity. 2015;43:527–40.PubMedCrossRef
34.
Murthy AK, Dubose CN, Banas JA, et al. Contribution of polymeric immunoglobulin receptor to regulation of intestinal inflammation in dextran sulfate sodium-induced colitis. J Gastroenterol Hepatol. 2006;21:1372–80.PubMed
35.
36.
Soyucen E, Gulcan A, Aktuglu-Zeybek AC, et al. Differences in the gut microbiota of healthy children and those with type 1 diabetes. Pediatr Int. 2014;56:336–43.PubMedCrossRef
37.
Maaser C, Housley MP, Iimura M, et al. Clearance of Citrobacter rodentium requires B cells but not secretory immunoglobulin A (IgA) or IgM antibodies. Infect Immun. 2004;72:3315–24.PubMedPubMedCentralCrossRef
38.
Reikvam DH, Derrien M, Islam R, et al. Epithelial-microbial crosstalk in polymeric Ig receptor deficient mice. Eur J Immunol. 2012;42:2959–70.PubMedCrossRef
39.
Wijburg OLC, Uren TK, Simpfendorfer K, et al. Innate secretory antibodies protect against natural Salmonella typhimurium infection. J Exp Med. 2006;203:21–6.PubMedPubMedCentralCrossRef
40.
Johnston PF, Gerding DN, Knight KL, et al. Protection from Clostridium difficile infection in CD4 T Cell- and polymeric immunoglobulin receptor-deficient mice. Infect Immun. 2014;82:522–31.PubMedPubMedCentralCrossRef
41.
Lycke N, Erlandsson L, Ekman L, et al. Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. J Immunol. 1999;163:913–9.PubMed
42.
Harriman GR, Bogue M, Rogers P, et al. Targeted deletion of the IgA constant region in mice leads to IgA deficiency with alterations in expression of other Ig isotypes. J Immunol. 1999;162:2521–9.PubMed
43.
44.
Friman V, Nowrouzian F, Adlerberth I, et al. Increased frequency of intestinal Escherichia coli carrying genes for S fimbriae and haemolysin in IgA-deficient individuals. Microb Pathog. 2002;32:35–42.PubMedCrossRef
45.
Kirpich IA, Marsano LS, McClain CJ, The Canadian Society of Clinical Chemists. Gut–liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem. 2015;48:923–30.PubMedPubMedCentralCrossRef
46.
47.
48.
Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412–25.PubMedCrossRef
49.
Hartmann P, Chen P, Wang HJ, et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology. 2013;58:108–19.PubMedCrossRef
50.
Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374–83.PubMedCrossRef
51.
Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137(1716–1724):e2.
52.
53.
Hartmann P, Chen W-C, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol. 2012;3:402.PubMedPubMedCentralCrossRef
54.
Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology. 2009;50:638–44.PubMedCrossRef
55.
Schäfer C, Parlesak A, Schütt C, et al. Concentrations of lipopolysaccharide-binding protein, bactericidal/permeability-increasing protein, soluble CD14 and plasma lipids in relation to endotoxaemia in patients with alcoholic liver disease. Alcohol Alcohol. 2002;37:81–6.PubMedCrossRef
56.
Bala S, Marcos M, Gattu A, et al. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS One. 2014;9:e96864.PubMedPubMedCentralCrossRef
57.
Fujimoto M, Uemura M, Nakatani Y, et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res. 2000;24:48S–54S.PubMedCrossRef
58.
Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940–7.PubMedCrossRef
59.
Lippai D, Bala S, Catalano D, et al. Micro-RNA-155 deficiency prevents alcohol-induced serum endotoxin increase and small bowel inflammation in mice. Alcohol Clin Exp Res. 2014;38:2217–24.PubMedPubMedCentralCrossRef
60.
Tabata T, Tani T, Endo Y, et al. Bacterial translocation and peptidoglycan translocation by acute ethanol administration. J Gastroenterol. 2002;37:726–31.PubMedCrossRef
61.
Verma VK, Li H, Wang R, et al. Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J Hepatol. 2016;64:651–60.PubMedCrossRef
62.
Iracheta-Vellve A, Petrasek J, Satishchandran A, et al. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice. J Hepatol. 2015;63:1147–55.PubMedPubMedCentralCrossRef
63.
64.
Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47:571–9.PubMedPubMedCentralCrossRef
65.
Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.PubMedCrossRef
66.
Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–81.PubMedCrossRef
67.
Kodama Y, Kisseleva T, Iwaisako K, et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology. 2009;137(1467–1477):e5.
68.
Alisi A, Manco M, Devito R, et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010;50:645–9.PubMedCrossRef
69.
Harte AL, da Silva NF, Creely SJ, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm. 2010;7:15.CrossRef
70.
71.
Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101:15718–23.PubMedPubMedCentralCrossRef
72.
73.
Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–131.PubMedCrossRef
74.
Dumas M-E, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA. 2006;103:12511–6.PubMedPubMedCentralCrossRef
75.
Nair S, Cope K, Terence RH, et al. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:1200–4.PubMedCrossRef
76.
Lee FI. Immunoglobulins in viral hepatitis and active alcoholic liver-disease. Lancet. 1965;2:1043–6.PubMedCrossRef
77.
Inamine T, Yang A-M, Wang L, et al. Genetic loss of immunoglobulin A does not influence development of alcoholic steatohepatitis in mice. Alcohol Clin Exp Res. 2016;40:2604–13.PubMedPubMedCentralCrossRef
78.
79.
Van De Wiel A, Delacroix DL, Van Hattum J, et al. Characteristics of serum IgA and liver IgA deposits in alcoholic liver disease. Hepatology. 1987;7:95–9.PubMedCrossRef
80.
81.
Souza HS, Elia CC, Braulio VB, et al. Effects of ethanol on gut-associated lymphoid tissues in a model of bacterial translocation: a possible role of apoptosis. Alcohol. 2003;30:183–91.PubMedCrossRef
82.
López MC. Chronic alcohol consumption regulates the expression of poly immunoglobulin receptor (pIgR) and secretory IgA in the gut. Toxicol Appl Pharmacol. 2017;333:84–91.PubMedCrossRef
83.
Budeč M, Markovic D, Vignjevic S, et al. Neuronal nitric oxide synthase mediates the effect of ethanol on IgA. Alcohol Alcohol. 2013;48:53–8.PubMedCrossRef
84.
Budeč M, Koko V, Todorović V, et al. Possible mechanism of acute effect of ethanol on intestinal IgA expression in rat. Int Immunopharmacol. 2007;7:858–63.PubMedCrossRef
85.
Budeč M, Todorović V, Drndarević N. Acute effect of ethanol on IgA immunoreactive cells in the intestine-associated immune system. Pharmacol Rep. 2005;57:385–9.PubMedCrossRef
86.
87.
Colombel JF, Vaerman JP, Mesnard B, et al. Jejunal immunoglobulin secretion in alcoholic patients with and without cirrhosis. J Hepatol. 1991;12:145–9.PubMedCrossRef
88.
Maier A, Bode C, Fritz P, et al. Effects of chronic alcohol abuse on duodenal mononuclear cells in man. Dig Dis Sci. 1999;44:691–6.PubMedCrossRef
89.
Tomita K, Teratani T, Yokoyama H, et al. Serum immunoglobulin A concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage. Dig Dis Sci. 2011;56:3648–54.PubMedCrossRef
90.
McPherson S, Henderson E, Burt AD, et al. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:1055–62.PubMedCrossRef
91.
Maleki I, Aminafshari MR, Taghvaei T, et al. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:12566–73.PubMedPubMedCentralCrossRef
92.
Okazaki Y, Han Y, Kayahara M, et al. Consumption of curcumin elevates fecal immunoglobulin A, an index of intestinal immune function, in rats fed a high-fat diet. J Nutr Sci Vitaminol. 2010;56:68–71.PubMedCrossRef
93.
Okazaki Y, Tomotake H, Tsujimoto K, et al. Consumption of a resistant protein, sericin, elevates fecal immunoglobulin A, mucins, and cecal organic acids in rats fed a high-fat diet. J Nutr. 2011;141:1975–81.PubMedCrossRef
94.
Matsumoto K, Ichimura M, Tsuneyama K, et al. Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. PLoS One. 2017;12:e0175406.PubMedPubMedCentralCrossRef
95.
Li S, Wu W-C, He C-Y, et al. Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats. World J Gastroenterol. 2008;14:3254–8.PubMedPubMedCentralCrossRef
96.
Taira T, Yamaguchi S, Takahashi A, et al. Dietary polyphenols increase fecal mucin and immunoglobulin A and ameliorate the disturbance in gut microbiota caused by a high fat diet. J Clin Biochem Nutr. 2015;57:212–6.PubMedPubMedCentralCrossRef
97.
Shin N-R, Whon TW, Bae J-W. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33:496–503.PubMedCrossRef
98.
Moon C, Baldridge MT, Wallace MA, et al. Vertically transmitted faecal IgA levels determine extra-chromosomal phenotypic variation. Nature. 2015;521:90–3.PubMedPubMedCentralCrossRef
99.
Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91:1–9.PubMedCrossRef
100.
Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096.PubMedPubMedCentralCrossRef
101.
Tian Y, Wang H, Yuan F, et al. Perilla oil has similar protective effects of fish oil on high-fat diet-induced nonalcoholic fatty liver disease and gut dysbiosis. Biomed Res Int. 2016;2016:9462571.PubMedPubMedCentral
102.
Raso GM, Simeoli R, Iacono A, et al. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and Toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem. 2014;25:81–90.PubMedCrossRef
103.
Rahman K, Desai C, Iyer SS, et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology. 2016;151(733–746):e12.
104.
Yin X, Peng J, Zhao L, et al. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. Syst Appl Microbiol. 2013;36:188–96.PubMedCrossRef
105.
Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764–75.PubMedCrossRef
106.
Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120–7.PubMedCrossRef
107.
Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011;53:96–105.PubMedCrossRef
108.
Bull-Otterson L, Feng W, Kirpich I, et al. Metagenomic analyses of alcohol-induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One. 2013;8:e53028.PubMedPubMedCentralCrossRef
109.
Wang L, Fouts DE, Stärkel P, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe. 2016;19:227–39.PubMedPubMedCentralCrossRef
110.
Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008;42:675–82.PubMedPubMedCentralCrossRef
111.
Bluemel S, Williams B, Knight R, et al. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016;311:G1018–36.PubMedPubMedCentralCrossRef
112.
113.
Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut. 2016;65:830–9.PubMedCrossRef
114.
115.
Heineke MH, van Egmond M. Immunoglobulin A: magic bullet or Trojan horse? Eur J Clin Invest. 2017;47:184–92.PubMedCrossRef
116.
Aleyd E, Heineke MH, van Egmond M. The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in disease. Immunol Rev. 2015;268:123–38.PubMedCrossRef
117.
van Egmond M, van Garderen E, van Spriel AB, et al. FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med. 2000;6:680–5.PubMedCrossRef
118.
Reljic R. In search of the elusive mouse macrophage Fc-alpha receptor. Immunol Lett. 2006;107:80–1.PubMedCrossRef
119.
van der Steen L, Tuk CW, Bakema JE, et al. Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology. 2009;137:2018–2029-3.
Metadata
Title
Immunoglobulin A and liver diseases
Authors
Tatsuo Inamine
Bernd Schnabl
Publication date
01-06-2018
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 6/2018
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-017-1400-8

Other articles of this Issue 6/2018

Journal of Gastroenterology 6/2018 Go to the issue

Letter to the Editor

Reply to the letter to the editor: Lymph node metastasis of adenocarcinoma and different definitions of sm1 cancer in the esophagus

Original Article—Liver, Pancreas, and Biliary Tract

Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma

Original Article—Alimentary Tract

Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children

Original Article—Liver, Pancreas, and Biliary Tract

Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C

Letter to the Editor

Basophils activated via TLR signaling may contribute to pathophysiology of type I autoimmune pancreatitis”

Original Article—Liver, Pancreas, and Biliary Tract

Nationwide survey for acute liver failure and late-onset hepatic failure in Japan

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits